ERICA: Evaluation of the Role of Inflammation in non pulmonary disease manifestations in Chronic Airways disease (COPD)

点击翻译按钮获取中文摘要

The project consists of three elements and seeks to determine the ability of fibrinogen to identify patients with COPD who have muscle and/or cardiovascular disease manifestations. The first part is focused on supporting Regulatory acceptance of clinical biomarkers representing the non-pulmonary disease subtype of COPD with the aim to ensure that assets in our Portfolio are not discarded due to an inappropriate clinical development plan. The second part includes a clinical trial with a novel Phase II anti-inflammatory in a selected subset of COPD patients with elevated blood fibrinogen to assess its effect on our chosen clinical biomarkers. The third part is an experimental medicine study with a Phase I novel drug candidate with an unprecedented mechanism of action which, together with the 2 other parts, may provide a path for a novel therapy for COPD patients at risk of cardiovascular-related events.